Thr175-phosphorylated tau induces pathologic fibril formation via GSK3β-mediated phosphorylation of Thr231 invitro

Neurobiology of Aging

Volumn 36, Issue 3, 2015, Pages 1590-1599

  Moszczynski, Alexander J ^a,b   Gohar, May ^b   Volkening, Kathryn ^a,b   Leystra Lantz, Cheryl ^b   Strong, Wendy ^b   Strong, Michael J ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Amyotrophic lateral sclerosis; Glycogen synthase kinase 3 ; Microtubule associated protein tau; Tauopathy

Indexed keywords

ASPARTIC ACID; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; GREEN FLUORESCENT PROTEIN; NOCODAZOLE; SHORT HAIRPIN RNA; TAU PROTEIN; THREONINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MAPT PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CELL DEATH; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; IN VITRO STUDY; MUTANT; NEURO2A CELL LINE; PATHOLOGIC FIBRIL FORMATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE, FUNCTION AND VARIABILITY; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; AMYOTROPHIC LATERAL SCLEROSIS; ANTAGONISTS AND INHIBITORS; BIOLOGY; CELL CULTURE; CHEMISTRY; GENE SILENCING; GENETICS; METABOLISM; NEUROFILAMENT; PATHOLOGY; PHOSPHORYLATION; PROTEIN MOTIF; TAUOPATHIES;

AMINO ACID MOTIFS; AMYOTROPHIC LATERAL SCLEROSIS; CELL DEATH; CELLS, CULTURED; COMPUTATIONAL BIOLOGY; GENE KNOCKDOWN TECHNIQUES; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; NEUROFIBRILS; PHOSPHORYLATION; RNA, SMALL INTERFERING; TAU PROTEINS; TAUOPATHIES; THREONINE;

EID: 84923637155     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.12.001     Document Type: Article

References (53)

1. Alonso A.D., Di C.J., Li B., Corbo C.P., Alaniz M.E., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J.Biol. Chem. 2010, 285:30851-30860.
2. Bhat R., Xue Y., Berg S., Hellberg S., Ormo M., Nilsson Y., Radesater A.C., Jerning E., Markgren P.O., Borgegard T., Nylof M., Gimenez-Cassina A., Hernandez F., Lucas J.J., Diaz-Nido J., Avila J. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J.Biol. Chem. 2003, 278:45937-45945.
3. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 2000, 33:95-130.
4. Chen J., Kanai Y., Cowan N.J., Hirokawa N. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature 1992, 360:674-677.
5. Cho J.H., Johnson G.V. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J.Biol. Chem. 2003, 278:187-193.
6. Cho J.H., Johnson G.V. Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ. J.Biol. Chem. 2004, 279:54716-54723.
7. Cho J.H., Johnson G.V. Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J.Neurochem. 2004, 88:349-358.
8. Combs B., Voss K., Gamblin T.C. Pseudohyperphosphorylation has differential effects on polymerization and function of tau isoforms. Biochemistry 2011, 50:9446-9456.
9. Ding S., Wu T.Y., Brinker A., Peters E.C., Hur W., Gray N.S., Schultz P.G. Synthetic small molecules that control stem cell fate. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:7632-7637.
10. Doble B.W., Woodgett J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J.Cell Sci. 2003, 116:1175-1186.
11. Dominguez J.M., Fuertes A., Orozco L., del Monte-Millan M., Delgado E., Medina M. Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J.Biol. Chem. 2012, 287:893-904.
12. Elamin M., Bede P., Byrne S., Jordan N., Gallagher L., Wynne B., O'Brien C., Phukan J., Lynch C., Pender N., Hardiman O. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology 2013, 80:1590-1597.
13. Elamin M., Phukan J., Bede P., Jordan N., Byrne S., Pender N., Hardiman O. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 2011, 76:1263-1269.
14. Factor-Litvak P., Al-Chalabi A., Ascherio A., Bradley W., Chio A., Garruto R., Hardiman O., Kamel F., Kasarskis E., McKee A., Nakano I., Nelson L.M., Eisen A. Current pathways for epidemiological research in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2013, 14(Suppl 1):33-43.
15. Friedhoff P., Schneider A., Mandelkow E.M., Mandelkow E. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry 1998, 37:10223-10230.
16. Garrido J.J., Simon D., Varea O., Wandosell F. GSK3 alpha and GSK3 beta are necessary for axon formation. FEBS Lett. 2007, 581:1579-1586.
17. Gohar M., Yang W., Strong W., Volkening K., Leystra-Lantz C., Strong M.J. Tau phosphorylation at threonine-175 leads to fibril formation and enhanced cell death: implications for amyotrophic lateral sclerosis with cognitive impairment. J.Neurochem. 2009, 108:634-643.
18. Hernandez F., Lucas J.J., Avila J. GSK3 and tau: two convergence points in Alzheimer's disease. J.Alzheimers Dis. 2013, 33(Suppl 1):S141-S144.
19. Hu W.T., Shelnutt M., Wilson A., Yarab N., Kelly C., Grossman M., Libon D.J., Khan J., Lah J.J., Levey A.I., Glass J. Behavior matters-cognitive predictors of survival in amyotrophic lateral sclerosis. PLoS One 2013, 8:e57584.
20. Jeganathan S., von B.M., Brutlach H., Steinhoff H.J., Mandelkow E. Global hairpin folding of tau in solution. Biochemistry 2006, 45:2283-2293.
21. Jordan M., Schallhorn A., Wurm F.M. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 1996, 24:596-601.
22. Kowall N.W., Kosik K.S. Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease. Ann. Neurol. 1987, 22:639-643.
23. Lau K.F., Miller C.C., Anderton B.H., Shaw P.C. Expression analysis of glycogen synthase kinase-3 in human tissues. J.Pept. Res. 1999, 54:85-91.
24. Lin Y.T., Cheng J.T., Liang L.C., Ko C.Y., Lo Y.K., Lu P.J. The binding and phosphorylation of Thr231 is critical for Tau's hyperphosphorylation and functional regulation by glycogen synthase kinase 3beta. J.Neurochem. 2007, 103:802-813.
25. Liu Y., Lv K., Li Z., Yu A.C., Chen J., Teng J. PACSIN1, a Tau-interacting protein, regulates axonal elongation and branching by facilitating microtubule instability. J.Biol. Chem. 2012, 287:39911-39924.
26. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001, 20:27-39.
27. Maurin H., Lechat B., Dewachter I., Ris L., Louis J.V., Borghgraef P., Devijver H., Jaworski T., Van Leuven F. Neurological characterization of mice deficient in GSK3alpha highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase. Mol. Brain 2013, 6:27.
28. Olney R.K., Murphy J., Forshew D., Garwood E., Miller B.L., Langmore S., Kohn M.A., Lomen-Hoerth C. The effects of executive and behavioral dysfunction on the course of ALS. Neurology 2005, 65:1774-1777.
29. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J.Neuropathol. Exp. Neurol. 1997, 56:70-78.
30. Pickhardt M., von B.M., Gazova Z., Hascher A., Biernat J., Mandelkow E.M., Mandelkow E. Screening for inhibitors of tau polymerization. Curr. Alzheimer Res. 2005, 2:219-226.
31. Ringholz G.M., Appel S.H., Bradshaw M., Cooke N.A., Mosnik D.M., Schulz P.E. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005, 65:586-590.
32. Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013, 14:248-264.
33. Sahara N., Murayama M., Lee B., Park J.M., Lagalwar S., Binder L.I., Takashima A. Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3beta is required for tau aggregation. Eur. J. Neurosci. 2008, 27:2897-2906.
34. Sato S., Tatebayashi Y., Akagi T., Chui D.H., Murayama M., Miyasaka T., Planel E., Tanemura K., Sun X., Hashikawa T., Yoshioka K., Ishiguro K., Takashima A. Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J.Biol. Chem. 2002, 277:42060-42065.
35. Sengupta A., Kabat J., Novak M., Wu Q., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 1998, 357:299-309.
36. Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Murphy J., Shoesmith C., Rosenfeld J., Leigh P.N., Bruijn L., Ince P., Figlewicz D. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2009, 10:131-146.
37. Strong M.J., Yang W., Strong W.L., Leystra-Lantz C., Jaffe H., Pant H.C. Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment. Neurology 2006, 66:1770-1771.
38. Sun Q., Gamblin T.C. Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization. Biochemistry 2009, 48:6002-6011.
39. Takahashi M., Tomizawa K., Kato R., Sato K., Uchida T., Fujita S.C., Imahori K. Localization and developmental changes of tau protein kinase I/glycogen synthase kinase-3 beta in rat brain. J.Neurochem. 1994, 63:245-255.
40. Taniguchi S., Suzuki N., Masuda M., Hisanaga S., Iwatsubo T., Goedert M., Hasegawa M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J.Biol. Chem. 2005, 280:7614-7623.
41. Uzbekova S., Salhab M., Perreau C., Mermillod P., Dupont J. Glycogen synthase kinase 3B in bovine oocytes and granulosa cells: possible involvement in meiosis during invitro maturation. Reproduction 2009, 138:235-246.
42. Vasquez R.J., Howell B., Yvon A.M., Wadsworth P., Cassimeris L. Nanomolar concentrations of nocodazole alter microtubule dynamic instability invivo and invitro. Mol. Biol. Cell 1997, 8:973-985.
43. von Bergen M., Friedhoff P., Biernat J., Heberle J., Mandelkow E.M., Mandelkow E. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5129-5134.
44. Wang Q.M., Park I.K., Fiol C.J., Roach P.J., DePaoli-Roach A.A. Isoform differences in substrate recognition by glycogen synthase kinases 3 alpha and 3 beta in the phosphorylation of phosphatase inhibitor 2. Biochemistry 1994, 33:143-147.
45. Weingarten M.D., Lockwood A.H., Hwo S.Y., Kirschner M.W. Aprotein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:1858-1862.
46. Wilson C.M., Grace G.M., Munoz D.G., He B.P., Strong M.J. Cognitive impairment in sporadic ALS: a pathologic continuum underlying a multisystem disorder. Neurology 2001, 57:651-657.
47. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9:2431-2438.
48. Yang W., Ang L.C., Strong M.J. Tau protein aggregation in the frontal and entorhinal cortices as a function of aging. Brain Res. Dev. Brain Res. 2005, 156:127-138.
49. Yang W., Leystra-Lantz C., Strong M.J. Upregulation of GSK3beta expression in frontal and temporal cortex in ALS with cognitive impairment (ALSci). Brain Res. 2008, 1196:131-139.
50. Yang W., Sopper M.M., Leystra-Lantz C., Strong M.J. Microtubule-associated tau protein positive neuronal and glial inclusions in ALS. Neurology 2003, 61:1766-1773.
51. Yang W., Strong M.J. Widespread neuronal and glial hyperphosphorylated tau deposition in ALS with cognitive impairment. Amyotroph. Lateral Scler. 2012, 13:178-193.
52. Yao H.B., Shaw P.C., Wong C.C., Wan D.C. Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain. J.Chem. Neuroanat. 2002, 23:291-297.
53. Yu J.Y., Taylor J., DeRuiter S.L., Vojtek A.B., Turner D.L. Simultaneous inhibition of GSK3alpha and GSK3beta using hairpin siRNA expression vectors. Mol. Ther. 2003, 7:228-236.